RT Journal Article SR Electronic T1 2022-RA-807-ESGO MLH1 promoter methylation analysis in patients with endometrial cancer stage I-II JF International Journal of Gynecologic Cancer JO Int J Gynecol Cancer FD BMJ Publishing Group Ltd SP A407 OP A408 DO 10.1136/ijgc-2022-ESGO.872 VO 32 IS Suppl 2 A1 Tripac, Irina A1 Stratan, Valentina A1 Tutuianu, Valeriu A1 Sitnic, Victor A1 Faraggi, David A1 Agius, Jean Calleja YR 2022 UL http://ijgc.bmj.com/content/32/Suppl_2/A407.2.abstract AB Introduction/Background The study included 50 patients diagnosed with endometrial cancer (EC) stage I-II. The age of these patients, on average, was 49.1 ± 12.1 years and ranged from 54 to 86 years.Methodology The tumor DNA was extracted from mapped formalin-fixed, paraffin-embedded tissue sections to provide tumor samples for the assays (figure 1).The methylation status of the MLH1 gene was determined using the Methylation Specific Polymerase Chain Reaction (MS-PCR) method and specific primers for both unmethylated and methylated fragments.Results The frequency of MLH1 promoter methylation was 20.0% and was determined in 10 patients. The frequency of tumors with MLH1 promoter methylation increases during menopause, reaching 30.0% at the age of 50–59 years and 50, 0% of cases at 60–69 years and decreases in the age periods 70–79 years, reaching 20.0%.The analysis of the obtained results showed that in patients with EC, the presence of MLH1 epimutation was significantly higher in stage I of the disease.Abstract 2022-RA-807-ESGO Figure 1 Methylation chain-specific polymerization reation workflowView this table:Abstract 2022-RA-807-ESGO Table 1 MLH1 dependence on stage of the disease in patients with endometrial cancer in stages I-IIThe presence of MLH1 epimutation was observed in 22.0% of patients with stage I EC and only in 2 stage II patients. The results of the analysis of overall survival in patients, according to the presence of MLH1 epimutation, showed that 71% of women with MLH1 epimutation and 92.5% without MLH1 epimutation survived at 3 years.Conclusion MLH1 promoter methylation analysis would play a valuable role as a clinical biomarker.